oHCM stands for obstructive hypertrophic cardiomyopathy, in which septal hypertrophy causes dynamic left ventricular outflow tract obstruction and symptomatic hemodynamic compromise.
Cytokinetics launches MYQORZO for obstructive hypertrophic cardiomyopathy following FDA approval, while C4 Therapeutics doses first patient in Phase 2 trial of cemsidomide for relapsed/refractory multiple myeloma.
The European Commission approved MYQORZO (aficamten) for treating symptomatic obstructive hypertrophic cardiomyopathy in adults, completing global regulatory approvals following FDA and China NMPA clearances. First European launch planned in Germany in Q2 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07483125 |
Valsalva SBP Drop and LVOT Obstruction |
RECRUITING |
